These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 12872337)
1. Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval. Markman M; DeMarco J Cancer; 2003 Jul; 98(2):215-8. PubMed ID: 12872337 [No Abstract] [Full Text] [Related]
3. The physician's role, "sham surgery," and trust: a conflict of duties? Clark CC Am J Bioeth; 2003; 3(4):57-8. PubMed ID: 14744337 [No Abstract] [Full Text] [Related]
4. Stocks' study renews concerns over insider trading on oncology drugs. Goozner M J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626 [No Abstract] [Full Text] [Related]
5. Better prioritization may speed approval of adjuvant therapies in breast cancer. Tuma RS J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735 [No Abstract] [Full Text] [Related]
6. Truth in advertising: FDA approval and the physician's responsibility. Knapp RM Anesthesiology; 1992 Mar; 76(3):477-8. PubMed ID: 1539866 [No Abstract] [Full Text] [Related]
7. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
8. The patient, the physician, and the regulator. Feinstein AR Forum Med; 1979 Oct; 2(10):652-6. PubMed ID: 10244158 [No Abstract] [Full Text] [Related]
11. Litigation plays protective role--and is part of the problem. Kennett JD Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818 [No Abstract] [Full Text] [Related]
12. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Peck CC; Rubin DB; Sheiner LB Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358 [No Abstract] [Full Text] [Related]
13. The approval process for hyperthermic intraoperative intraperitoneal chemotherapy. Sugarbaker PH; Clarke L Eur J Surg Oncol; 2006 Aug; 32(6):637-43. PubMed ID: 16630703 [TBL] [Abstract][Full Text] [Related]
14. Conflict of interest and physician dispensing. Olch DI Internist; 1987 Oct; 28(9):13-6, 24. PubMed ID: 10284543 [No Abstract] [Full Text] [Related]
15. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228 [TBL] [Abstract][Full Text] [Related]
16. Expanded access to Phase II clinical trials in oncology: a step toward increasing scientific validity and compassion. Marcee AK Food Drug Law J; 2008; 63(2):439-57. PubMed ID: 18561471 [No Abstract] [Full Text] [Related]
17. Accelerated approval of oncology products: a decade of experience. Dagher R; Johnson J; Williams G; Keegan P; Pazdur R J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600 [TBL] [Abstract][Full Text] [Related]
19. Accelerated approval seen as triumph and roadblock for cancer drugs. Susman E J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596 [No Abstract] [Full Text] [Related]
20. Cancer drug approval in the United States, Europe, and Japan. Milsted RA Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686 [No Abstract] [Full Text] [Related] [Next] [New Search]